SCH-50911: Difference between revisions
CSV import |
CSV import |
||
| Line 22: | Line 22: | ||
{{stub}} | {{stub}} | ||
== SCH-50911 == | |||
<gallery> | |||
File:SCH-50911.svg|SCH-50911 | |||
</gallery> | |||
Latest revision as of 21:10, 25 February 2025
SCH-50911 is a drug that acts as a GABA antagonist, specifically at GABA_B receptors. It was the first selective GABA_B antagonist to be discovered and researched. SCH-50911 has been used in the research of various types of pharmacology and neurology, including studies of epilepsy, anxiety, depression, and drug addiction.
Pharmacology[edit]
SCH-50911 is a GABA_B receptor antagonist. It works by blocking the action of the neurotransmitter GABA on GABA_B receptors. This results in an increase in the release of other neurotransmitters, such as dopamine and serotonin, which can have various effects on the body and brain.
Uses[edit]
SCH-50911 has been used in research to study the role of GABA_B receptors in various conditions. These include epilepsy, where it has been found to reduce the frequency and severity of seizures; anxiety, where it has been found to have anxiolytic effects; depression, where it has been found to have antidepressant effects; and drug addiction, where it has been found to reduce the rewarding effects of addictive drugs.
Side Effects[edit]
As with all drugs, SCH-50911 can have side effects. These can include nausea, vomiting, dizziness, and headache. However, these side effects are generally mild and temporary.
